Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
LadRx Corporation (LadRx, ticker LADX) is a clinical-stage biopharmaceutical company focused on the development of oncology therapeutics. The company operates within the biotechnology and pharmaceutical industry, with activities centered on advancing drug candidates for the treatment of cancer, particularly solid tumors with significant unmet medical need. LadRx does not currently generate product revenue and relies primarily on equity financing, licensing arrangements, and strategic transactions to fund operations.
The company’s primary historical asset has been aldoxorubicin, a modified form of the chemotherapy drug doxorubicin designed to improve targeted delivery and reduce systemic toxicity. LadRx evolved from its predecessor, CytRx Corporation, which was founded in 1986 and rebranded to LadRx Corporation in 2023 as part of a strategic realignment emphasizing oncology-focused drug development and asset monetization. The company’s positioning has been as a niche oncology developer seeking value through selective clinical advancement, licensing, or asset sales rather than large-scale commercialization.
Business Operations
LadRx’s business operations are organized around oncology drug development, with activities primarily consisting of clinical trial oversight, regulatory strategy, intellectual property management, and evaluation of strategic alternatives for its assets. The company’s operations are largely outsourced, relying on third-party contract research organizations (CROs) and manufacturing partners rather than maintaining in-house manufacturing or large research facilities.
The company’s operations are predominantly based in the United States, with international activity occurring through clinical trials and regulatory interactions in select foreign jurisdictions. LadRx does not report multiple operating segments; instead, it functions as a single reporting unit focused on therapeutic development. Data on current active partnerships or revenue-generating subsidiaries is limited, and public disclosures indicate that operational scale has been intentionally kept lean to preserve capital. Where current operational status of specific programs is concerned, data inconclusive based on available public sources.
Strategic Position & Investments
Strategically, LadRx has emphasized maximizing shareholder value through strategic transactions, including licensing, partnerships, or potential divestiture of its oncology assets rather than independently funding late-stage clinical development. The company has publicly stated its intent to explore alternatives for aldoxorubicin and related intellectual property, reflecting a capital-efficient approach common among micro-cap biotechnology firms.
LadRx has not disclosed significant recent acquisitions or a diversified investment portfolio. Its strategy has instead focused on maintaining ownership of core intellectual property while remaining open to collaboration with larger pharmaceutical or biotechnology partners. Public filings indicate ongoing evaluation of additional oncology-related opportunities; however, specific investments in emerging technologies or new therapeutic platforms have not been conclusively verified.
Geographic Footprint
LadRx is headquartered in the United States, with corporate offices historically located in California. The company’s operational footprint is limited, reflecting its status as a clinical-stage developer without commercial manufacturing or sales infrastructure. Most corporate functions, including executive management and regulatory oversight, are U.S.-based.
International presence is indirect and primarily related to clinical development activities, such as multinational clinical trials and regulatory consultations outside the U.S. LadRx does not report significant physical operations, subsidiaries, or owned facilities in Europe, Asia, or other regions, and its global influence is primarily intellectual property–driven rather than operational.
Leadership & Governance
LadRx is governed by a board of directors and a lean executive leadership team with experience in biotechnology, finance, and public company governance. The company’s leadership philosophy emphasizes capital discipline, asset-focused development, and strategic flexibility in pursuing partnerships or transactions.
Key executives and leaders include:
- John W. Barr – Chairman of the Board
- Wayne P. Goddard – Chief Executive Officer
- Anthony Cataldo – Chief Financial Officer
- Leonard E. Mazur – Director
Public disclosures indicate that management and the board play an active role in strategic decision-making due to the company’s limited operational scale. Information regarding founder involvement beyond historical context is limited, and no formal founder-led governance structure has been identified in recent public filings.